Benign Prostatic Hyperplasia Bph Epidemiology Forecast

DelveInsight's 'Benign prostatic hyperplasia (BPH) - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Benign prostatic hyperplasia (BPH) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.


Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan


Study Period: 2017-2030


Benign prostatic hyperplasia (BPH) Understanding

The DelveInsight Benign prostatic hyperplasia (BPH) epidemiology report gives a thorough understanding of the Benign prostatic hyperplasia (BPH) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Benign prostatic hyperplasia (BPH) in the US, Europe, and Japan. The report covers the detailed information of the Benign prostatic hyperplasia (BPH) epidemiology scenario in seven major countries (US, EU5, and Japan).


Benign prostatic hyperplasia (BPH) Epidemiology Perspective by DelveInsight

The Benign prostatic hyperplasia (BPH) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Benign prostatic hyperplasia (BPH) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Benign prostatic hyperplasia (BPH) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.


Benign prostatic hyperplasia (BPH) Detailed Epidemiology Segmentation

The Benign prostatic hyperplasia (BPH) epidemiology covered in the report provides historical as well as forecasted Benign prostatic hyperplasia (BPH) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight Benign prostatic hyperplasia (BPH) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.


Scope of the Report

  • The Benign prostatic hyperplasia (BPH) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Benign prostatic hyperplasia (BPH) Epidemiology Report and Model provide an overview of the risk factors and global trends of Benign prostatic hyperplasia (BPH) in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Benign prostatic hyperplasia (BPH) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Benign prostatic hyperplasia (BPH)
  • The report provides the segmentation of the Benign prostatic hyperplasia (BPH) epidemiology


Report Highlights

  • 11-Year Forecast of Benign prostatic hyperplasia (BPH) epidemiology
  • 7MM Coverage
  • Total Cases of Benign prostatic hyperplasia (BPH)
  • Total Cases of Benign prostatic hyperplasia (BPH) according to segmentation
  • Diagnosed cases of Benign prostatic hyperplasia (BPH)


KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.


Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Benign prostatic hyperplasia (BPH)?
  • What are the key findings pertaining to the Benign prostatic hyperplasia (BPH) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Benign prostatic hyperplasia (BPH) across the 7MM during the forecast period (2017-2030)?
  •  Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Benign prostatic hyperplasia (BPH)?
  • What are the currently available treatments of Benign prostatic hyperplasia (BPH)?


Reasons to buy

  • The Benign prostatic hyperplasia (BPH) Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Benign prostatic hyperplasia (BPH) market
  • Quantify patient populations in the global Benign prostatic hyperplasia (BPH) market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Benign prostatic hyperplasia (BPH) therapeutics in each of the markets covered
  • Understand the magnitude of Benign prostatic hyperplasia (BPH) population by its epidemiology
  • The Benign prostatic hyperplasia (BPH) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources


Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights 

2. Executive Summary of Benign prostatic hyperplasia (BPH)

3. Benign prostatic hyperplasia (BPH): Disease Background and Overview

3.1. Introduction

3.2. Sign and Symptoms

3.3. Pathophysiology

3.4. Risk Factors

3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 7MM

5.3. Epidemiology Scenario: 7MM

5.3.1. Benign prostatic hyperplasia (BPH) Epidemiology Scenario in the 7MM (2017- 2030)

5.4. United States Epidemiology

5.4.1. Benign prostatic hyperplasia (BPH) Epidemiology Scenario in the United States (2017- 2030)

5.5. EU-5 Country-wise Epidemiology

5.5.1. Germany Epidemiology

5.5.1.1. Benign prostatic hyperplasia (BPH) Epidemiology Scenario in Germany (2017- 2030)

5.5.2. France Epidemiology

5.5.2.1. Benign prostatic hyperplasia (BPH) Epidemiology Scenario in France (2017- 2030)

5.5.3. Italy Epidemiology

5.5.3.1. Benign prostatic hyperplasia (BPH) Epidemiology Scenario in Italy (2017- 2030)

5.5.4. Spain Epidemiology

5.5.4.1. Benign prostatic hyperplasia (BPH) Epidemiology Scenario in Spain (2017- 2030)

5.5.5. United Kingdom Epidemiology

5.5.5.1. Benign prostatic hyperplasia (BPH) Epidemiology Scenario in the United Kingdom (2017-2030)

5.6. Japan Epidemiology

5.6.1. Benign prostatic hyperplasia (BPH) Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

6.1. Benign prostatic hyperplasia (BPH) Treatment and Management

6.2. Benign prostatic hyperplasia (BPH) Treatment Algorithm

7. KOL Views

8. Unmet Needs

9.  Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

*The table of contents is not exhaustive; will be provided in the final report

Table 1  Benign prostatic hyperplasia (BPH) Epidemiology in 7MM (2017-2030)

Table 2 Benign prostatic hyperplasia (BPH) Diagnosed and Treatable Cases in 7MM (2017-2030)

Table 3 Benign prostatic hyperplasia (BPH) Epidemiology in the United States (2017-2030)

Table 4 Benign prostatic hyperplasia (BPH) Diagnosed and Treatable Cases in the United States (2017-2030)

Table 5 Benign prostatic hyperplasia (BPH) Epidemiology in Germany (2017-2030)

Table 6 Benign prostatic hyperplasia (BPH) Diagnosed and Treatable Cases in Germany (2017-2030)

Table 7 Benign prostatic hyperplasia (BPH) Epidemiology in France (2017-2030)

Table 8 Benign prostatic hyperplasia (BPH) Diagnosed and Treatable Cases in France (2017-2030)

Table 9 Benign prostatic hyperplasia (BPH) Epidemiology in Italy (2017-2030)

Table 10 Benign prostatic hyperplasia (BPH) Diagnosed and Treatable Cases in Italy (2017-2030)

Table 11 Benign prostatic hyperplasia (BPH) Epidemiology in Spain (2017-2030)

Table 12 Benign prostatic hyperplasia (BPH) Diagnosed and Treatable Cases in Spain (2017-2030)

Table 13 Benign prostatic hyperplasia (BPH) Epidemiology in the United Kingdom (2017-2030)

Table 14 Benign prostatic hyperplasia (BPH) Diagnosed and Treatable Cases in the United Kingdom (2017-2030)

Table 15 Benign prostatic hyperplasia (BPH) Epidemiology in Japan (2017-2030)

Table 16 Benign prostatic hyperplasia (BPH) Diagnosed and Treatable Cases in Japan (2017-2030)

Figure 1 Benign prostatic hyperplasia (BPH) Epidemiology in 7MM (2017-2030)

Figure 2 Benign prostatic hyperplasia (BPH) Diagnosed and Treatable Cases in 7MM (2017-2030)

Figure 3 Benign prostatic hyperplasia (BPH) Epidemiology in the United States (2017-2030)

Figure 4 Benign prostatic hyperplasia (BPH) Diagnosed and Treatable Cases in the United States (2017-2030)

Figure 5 Benign prostatic hyperplasia (BPH) Epidemiology in Germany (2017-2030)

Figure 6 Benign prostatic hyperplasia (BPH) Diagnosed and Treatable Cases in Germany (2017-2030)

Figure 7 Benign prostatic hyperplasia (BPH) Epidemiology in France (2017-2030)

Figure 8 Benign prostatic hyperplasia (BPH) Diagnosed and Treatable Cases in France (2017-2030)

Figure 9 Benign prostatic hyperplasia (BPH) Epidemiology in Italy (2017-2030)

Figure 10 Benign prostatic hyperplasia (BPH) Diagnosed and Treatable Cases in Italy (2017-2030)

Figure 11 Benign prostatic hyperplasia (BPH) Epidemiology in Spain (2017-2030)

Figure 12 Benign prostatic hyperplasia (BPH) Diagnosed and Treatable Cases in Spain (2017-2030)

Figure 13 Benign prostatic hyperplasia (BPH) Epidemiology in the United Kingdom (2017-2030)

Figure 14 Benign prostatic hyperplasia (BPH) Diagnosed and Treatable Cases in the United Kingdom (2017-2030)

Figure 15 Benign prostatic hyperplasia (BPH) Epidemiology in Japan (2017-2030)

Figure 16 Benign prostatic hyperplasia (BPH) Diagnosed and Treatable Cases in Japan (2017-2030)

*The table of contents is not exhaustive; will be provided in the final report



  • Tags:
  • Benign prostatic hyperplasia (BPH)...
  • Benign prostatic hyperplasia (BPH)
  • Benign prostatic hyperplasia (BPH)...
  • Benign prostatic hyperplasia (BPH)...
  • Benign prostatic hyperplasia (BPH)...
  • Benign prostatic hyperplasia (BPH)...
  • Benign prostatic hyperplasia (BPH)...
  • Benign prostatic hyperplasia (BPH)...

Forward to Friend

Need A Quote